To investigate the effect of antihypertensive therapy on ventricular -arterial mechanics, coupling, and efficiency in early-stage hypertension.
Introduction
Hypertension is the most common risk factor for heart failure, 1 specifically heart failure with preserved ejection fraction (HFpEF). 2 Both arterial and left ventricular (LV) stiffening may contribute to the transition from asymptomatic hypertensive heart disease to overt HFpEF. 3 -6 The functional interaction between the LV and arterial systems, termed ventricular-arterial coupling, is recognized as a key determinant of cardiovascular performance. 7, 8 While effective antihypertensive therapy is a central component of heart failure prevention, 9 the mechanisms by which blood pressure control decrease heart failure risk are not fully established. The extent to which antihypertensive therapy reverses arterial and LV systolic stiffness, or affects ventricular-arterial coupling and LV energetic efficiency, is not well understood. Further, a number of factors, including sex, body size, and age, are known to influence ventricular-arterial properties, 10 -15 yet how these factors may influence the ventricular -arterial response to antihypertensive therapy remains unclear. We utilized data from subjects prospectively enrolled in the Valsartan in Diastolic Dysfunction (VALIDD) 16 and Exforge Intensive
Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction (EXCEED) 17 trials to systematically evaluate the effect of antihypertensive therapy on ventricular-arterial mechanics, efficiency, and coupling among hypertensive adults with diastolic dysfunction, as well as in groups at greater risk for HFpEF.
Methods Study population
A total of 527 participants of the VALIDD 16 and EXCEED 17 trials were studied. These trials tested the effect of antihypertensive strategies on diastolic function reflected in the lateral mitral annular early relaxation velocity (e ′ ), and shared the following key inclusion criteria: (i) age ≥45 years; (ii) the presence of diastolic dysfunction defined by a lateral e ′ ,10 cm/s in subjects 45 -54 years old, ,9 cm/s in subjects 55 -65 years old, and ,8 cm/s in subjects .65 years old; (iii) LV ejection fraction (EF) .50%; and (iv) absence of heart failure symptoms. Both studies excluded patients with severe hypertension or known intolerance to an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. EXCEED also excluded patients with diabetes mellitus. In brief, VALIDD was a prospective randomized multicentre trial of valsartan vs. placebo (along with antihypertensive therapy not blocking the renin -angiotensin system) in patients with a systolic blood pressure (SBP) between 140 and 180 mmHg or diastolic blood pressure of 90-100 mmHg and reduced lateral e ′ ; all treated to a target SBP of ,135 mmHg. EXCEED was a prospective randomized multicentre trial of intensive vs. standard blood pressure lowering (target SBP ,130 vs. ,140 mmHg respectively), using a combination of valsartan plus amlodipine and other hypertensive medications as needed, in patients with an SBP between 150 and 200 mmHg or on two antihypertensive agents and reduced lateral e ′ . Detailed protocols for the VALIDD 16, 18 and EXCEED 17, 19 trials have been published, and derivation of the current study sample is described in Supplementary material online, Methods. The combined sample included 527 men and women aged ≥45 years with Stage 1 or 2 hypertension, no heart failure, EF ≥50%, and diastolic dysfunction, uniformly undergoing echocardiographic assessments before and after controlled antihypertensive therapy.
Assessment of ventricular and arterial properties
All echocardiograms from both trials were analysed in the same core laboratory. Arterial stiffness was characterized as effective arterial elastance (Ea) 20 and estimated as end-systolic pressure divided by stroke volume. 21 To further characterize arterial loading, the individual components of arterial load were determined: total arterial compliance (ratio of stroke volume to pulse pressure) and total peripheral resistance (mean arterial pressure divided by cardiac output × 80). Left ventricular systolic stiffness was characterized as end-systolic elastance (Ees) using the modified single-beat method. 22, 23 Since Ees is influenced by passive chamber stiffening and remodelling, additional measures of performance (LV EF, LV stroke work ¼ end-systolic pressure × stroke volume) and contractility (stroke work index ¼ stroke work/end-diastolic volume) were determined. The ratio of Ea/Ees was used as an index of ventricular -arterial coupling, 20 as previously validated 10, 13 and widely applied in clinical studies. To further understand the association of ventricular-arterial coupling with energy efficiency of the LV, we used the pressure -volume area (PVA) concept proposed by Suga et al., 24, 25 where PVA represents the total mechanical energy of contraction and correlates with myocardial oxygen consumption. LV energetic efficiency was then determined as the ratio of stroke work to PVA. Detailed echocardiographic and statistical methods are described in Supplementary material online, Methods.
Results

Baseline characteristics
The study sample included predominantly white men and women, mean age 60 years, with Stage 1 hypertension, and low prevalence of co-existing cardiovascular conditions ( Table 1 ). There were no significant differences in age, sex, body mass index, race, renal function, prevalence of atrial fibrillation, or history of cardiovascular disease across quartiles of reduction in SBP. The lower prevalence of diabetes in those achieving greater reductions in blood pressure was expected by trial design (diabetic patients were excluded in EXCEED). Those achieving greater reductions in SBP had greater Ea, more LV hypertrophy, greater LV stroke work, and greater myocardial oxygen consumption (PVA) at baseline, consistent with their higher baseline SBP. Of note, baseline Ea/Ees ratio and LV energetic efficiency was similar across quartiles of SBP change.
Changes in cardiovascular form and function with antihypertensive therapy
Ea and Ees decreased with antihypertensive therapy, with a more prominent effect on the former such that the coupling ratio (Ea/ Ees) decreased (all P , 0.001, Table 2 ). The reduction in Ea occurred in tandem with reductions in both resistive (total peripheral resistance) and pulsatile (total arterial compliance) load.
Antihypertensive therapy was also associated with reductions in LV size, mass, wall thickness and concentricity (LV mass/enddiastolic volume). Ejection fraction increased while stroke work and PVA decreased, with a modest improvement in LV energetic efficiency. The e ′ velocity increased while E/e ′ ratio and plasma NT-proBNP levels decreased, consistent with improved LV diastolic function. The changes in ventricular-arterial mechanics, coupling, and efficiency were consistent across trial/treatment arms (see Supplementary material online, Table S1 ), even though effect size and statistical significance were influenced by the degree of blood pressure lowering and sample size in each trial arm. Changes in Ea/Ees ratio were inversely correlated with those in EF (r ¼ 20.25; P , 0.001), stroke work index (r ¼ 20.13; P ¼ 0.007), and LV efficiency (r ¼ 20.98; P , 0.001); and directly related to changes in E/e ′ (r ¼ 0.12; P ¼ 0.01).
Association between degree of blood pressure lowering and change in arterial and LV systolic stiffness
Ea and Ees decreased to greater extent with greater reductions in SBP ( Table 2) . These relationships persisted after adjusting for age, Therapy and ventricular -vascular coupling sex, body mass index, history of cardiovascular disease, diabetes mellitus, atrial fibrillation, estimated glomerular filtration rate, and baseline SBP ( Table 3) . In contrast, the extent of change in ventricular -arterial coupling (Ea/Ees) was unrelated to SBP reduction. Improvements in EF, stroke work, stroke work index, PVA, and diastolic parameters were each related to the degree of SBP reduction.
Impact of sex, obesity, and age
There was no significant difference in baseline, follow-up, or change in SBP between men and women, or between obese (BMI.30 kg/m 2 ) and non-obese individuals (see Supplementary material online, Table S2 ). There was a trend towards higher SBP at follow-up in those above the median age of 60 years compared (9) 15 (12) 13 (10) 8 (6) 12 (9) 0.37 Diabetes mellitus [n (%)]
41 (8) 15 (12) 14 (11) 5 (4) 7 (5) 0.03 (11) 6 (5) 5 (1) 22 (5) 21 (4) ,0.001
Angiotensin receptor blockers 62 (13) 15 (3) 13 (3) 17 (4) 17 (4) Therapy and ventricular -vascular coupling with younger individuals, but no significant difference in the change in SBP with antihypertensive therapy between age groups. Women had higher arterial (Ea) and LV end-systolic (Ees) stiffness than men at baseline and follow-up (all P , 0.001) (Figure 1 , top row). These sex-differences in Ea and Ees were no longer statistically significant after indexing each parameter to body surface area. However, independent of indexation, there was a significant sex difference in the change in the coupling ratio (Ea/Ees) from ; black circles), and below median age 60 years (black triangles) vs. at or above 60 years of age (green circles). P-values represent comparisons of change in variable of interest (Ea, Ees, Ea/Ees or efficiency) between men and women (top row), obese and non-obese (middle row), or age above and below median (bottom row), adjusting for degree of blood pressure lowering, age and BMI (top row), age and sex (middle row), or sex and BMI (bottom row). *Significant differences between groups at baseline or follow-up.
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baseline to follow-up: this change was significantly smaller in women than men, even after adjusting for age, change in SBP, and body mass index (P ¼ 0.04). The improvement in LV efficiency from baseline to follow-up was similarly blunted in women compared with men (adjusted P ¼ 0.04).
Obesity was associated with lower Ea at baseline and follow-up (P ¼ 0.001), and disproportionately lower Ees at follow-up (P , 0.001), such that the Ea/Ees ratio was higher in obese individuals at follow-up (P ¼ 0.01) (Figure 1, middle row) . The change in Ea/ Ees ratio was significantly smaller in obese than non-obese individuals, adjusting for age, change in SBP, and sex (P ¼ 0.007). The improvement in LV efficiency from baseline to follow-up was similarly blunted in obese compared with non-obese individuals (adjusted P ¼ 0.004).
Older age (≥60 years) was associated with higher Ea and higher Ees, both at baseline and follow-up, compared with age,60 years (all P ≤ 0.001) (Figure 1, bottom row) . The Ea/Ees ratio was not significantly different between those above and below 60 years of age at baseline and follow-up. The changes in Ea/Ees ratio (adjusted P ¼ 0.96) and LV efficiency (adjusted P ¼ 0.65) from baseline to follow-up were also similar in those above and below 60 years of age.
Discussion
We found that in the early stages of hypertension, antihypertensive therapy reduced arterial and LV systolic stiffness, lowered the ventricular-arterial coupling ratio, and reduced cardiac work while improving efficiency. This reversal of hypertensive arterial and LV systolic stiffness was directly related to the degree of blood pressure lowering and occurred in parallel with modest reductions in LV mass and concentric remodelling. The reduction in the coupling ratio correlated with improvements in LV systolic and diastolic function, as well as enhancement of cardiac efficiency. These improvements were similar in older (≥60 years) compared with younger individuals, but were attenuated in women compared with men, and in obese compared with non-obese individuals.
In the current study, we found that blood pressure lowering led to tandem reductions in arterial and LV systolic stiffness in patients with early-stage hypertension treated for 24 -38 weeks. The reduction in arterial stiffness was out of proportion to that in LV systolic stiffness, such that the ventricular -arterial coupling ratio decreased. Of note, this reduction in the coupling ratio correlated with improvements in LV systolic and diastolic function, reduction in cardiac work, and enhancement of LV efficiency. We further demonstrated a direct linear relationship between the degree of blood pressure lowering and the extent of reduction in separate components of arterial and LV systolic stiffness. These changes were associated with concurrent reductions in LV mass and B-type natriuretic peptide levels. In aggregate, these data suggest that the benefit of antihypertensive therapy in reducing the Ea/ Ees ratio is that less mechanical work is needed to achieve similar cardiac output, thus reducing concentric remodelling and myocardial oxygen demand.
Previous studies have established that hypertensive individuals display increased arterial and LV systolic stiffness compared with normotensive controls, while women show evidence for greater ventricular -arterial stiffening than men. 15 In prior reports, the coupling ratio (Ea/Ees) did not differ between hypertensive and normotensive men, suggesting that the increases in arterial (Ea) and LV systolic (Ees) stiffness in hypertensive men were matched. In contrast, the coupling ratio was 23% lower in hypertensive compared with normotensive women. 14 The lower ratio in hypertensive women implied a disproportionate increase in LV systolic compared with arterial stiffness, suggesting either an adaptation in women to limit the impact of hypertension on the vasculature or, alternatively, a more pronounced impact of hypertension on the left ventricle vs. the arteries. The former is less likely, given epidemiological evidence that outward aortic remodelling may be blunted in women, and related to greater aortic impedance and arterial load in women compared with men. 26, 27 On the other hand, the latter is supported by data showing a greater extent of concentric LV remodelling in hypertensive women compared with men, and the presence of sex-related differences in oestrogen receptor signalling in cardiomyocytes. 28 Prior studies did not specifically evaluate the impact of antihypertensive therapy on ventricular-arterial coupling and were limited by relatively small numbers of hypertensive patients and retrospective design. We found that sex and body size were important determinants of the change in the coupling ratio and improvement in cardiac efficiency with antihypertensive therapy, with women and obese individuals showing smaller reductions in the coupling ratio, and smaller improvements in cardiac efficiency, compared with men and non-obese individuals. The attenuated responses in women and in obese individuals may provide insight into the mechanisms underlying progression of hypertensive heart disease despite therapy, and the predisposition of these individuals to the development of heart failure even in the presence of preserved EF. This progression involves the development of asymptomatic LV hypertrophy (typically concentric, unless there is interim myocardial infarction) followed by transition to symptomatic HFpEF. 29 HFpEF is known to predominantly affect women and obese individuals. We postulate that the smaller impact of antihypertensive therapy on VA coupling in women and obese individuals may lead to greater mechanical inefficiency and greater compensatory LV remodelling in these at-risk groups. With progression of disease, this remodelling process is associated with loss of LV contractile and diastolic reserve, resulting in the development of symptomatic HFpEF. All subgroups in our study derived benefit from blood pressure control in terms of improvement in ventricular-arterial mechanics and efficiency (albeit to different degrees), including elderly hypertensive patients. Our findings suggest that judicious blood pressure control may be one way to prevent progression of hypertensive heart disease to decompensated HFpEF, via preservation of ventricular -arterial mechanics and efficiency, and support guideline recommendations for effective blood pressure control even in the early stages of disease.
Limitations
The inclusion of patients from two separate clinical trials is a limitation of our study design. The VALIDD and EXCEED trials shared common major inclusion criteria and a common imaging endpoint. The trials had minor differences in inclusion criteria, with the exception of baseline blood pressure which was higher in EXCEED, thus allowing us to explore effects across a wide range of blood pressure lowering in this study. Nevertheless, we carefully adjusted for trial in our analysis and examined results stratified by trial/treatment strategy arm to ensure consistency. Treatment strategy arms in both trials involved multiple types of antihypertensive drugs to reach common blood pressure treatment goals, and details of specific drug changes were not available to allow analyses by type of drug-an important area that merits future study. While invasive methods are the gold standard to characterize ventricular -arterial mechanical properties, repeated invasive studies would not have been feasible in this large sample. We recognize the collinearity between measurements of SBP and Ea, as well as between SBP and Ees. However, this neither impacts the Ea/Ees ratio nor influences other independent measurements of LV structure, function, and NT-proBNP levels. Brachial rather than central aortic pressure was used, which ignores the effects of peripheral pulse wave amplification. Measurements were made in a uniform manner throughout the study, and comparisons were chiefly made using the same participant as his/her own control. Thus, any systematic deviation from true measurements was equally likely in all participants, making them less likely to affect the validity of the findings. Clinical outcomes were not available in this study, but the Ea/Ees ratio has been shown to predict cardiovascular mortality in patients with prior myocardial infarctions, 30 and its prognostic utility in the setting of hypertensive heart disease warrants further study.
Conclusion
Antihypertensive therapy reduces arterial and LV systolic stiffness, lowers the ventricular -arterial coupling ratio, and reduces stroke work while improving energetic efficiency in hypertensive patients with diastolic dysfunction. The reduction in arterial and LV systolic stiffness is directly related to the degree of blood pressure lowering and occurs in parallel with modest improvements in LV structure and function, thus underscoring the benefits of effective blood pressure control in hypertensive heart disease. The attenuated responses in women and obese individuals may provide insight into the mechanisms underlying progression of hypertensive heart disease to HFpEF in these at-risk groups, and represent areas for future study to prevent HF progression.
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